Qyuns Therapeutics Out-Licenses QX027N Globally in Deal Worth Up to US$700 Million

Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has issued an announcement.

Qyuns Therapeutics has signed a license and collaboration agreement with LE2025 Therapeutics AG, an affiliate of Switzerland-based Windward Bio Group AG, granting LE2025 exclusive rights to develop and commercialize its long-acting anti-TSLPxIL-13 bispecific antibody QX027N outside mainland China, Taiwan, Hong Kong and Macau. Under the deal, Qyuns is eligible to receive up to US$700 million in upfront, equity, development and commercial milestone payments, as well as tiered royalties on QX027N sales in the licensed territories, marking a significant monetisation of its immunology pipeline and expanding the global development footprint of a candidate now in Phase I trials in China, while shareholders are cautioned about trading in the company’s shares.

The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.

More about Qyuns Therapeutics Co., Ltd. Class H

Qyuns Therapeutics Co., Ltd. is a China-based biopharmaceutical company focused on developing innovative antibody therapies for immunological diseases, particularly in respiratory and dermatological indications such as asthma and atopic dermatitis. Its pipeline includes QX027N, a long-acting anti-TSLPxIL-13 bispecific antibody that recently entered Phase I clinical development in China following approvals from the National Medical Products Administration.

Average Trading Volume: 581,570

Technical Sentiment Signal: Hold

Current Market Cap: HK$4.27B

Learn more about 2509 stock on TipRanks’ Stock Analysis page.